Mujdat Zeybel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3133816/publications.pdf

Version: 2024-02-01

1163117 1372567 10 399 8 10 citations h-index g-index papers 12 12 12 769 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. Gut, 2017, 66, 1321-1328.	12.1	172
2	A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A. Molecular Therapy, 2017, 25, 218-231.	8.2	65
3	The Potential Use of Metabolic Cofactors in Treatment of NAFLD. Nutrients, 2019, 11, 1578.	4.1	37
4	Multiomics Analysis Reveals the Impact of Microbiota on Host Metabolism in Hepatic Steatosis. Advanced Science, 2022, 9, e2104373.	11.2	23
5	Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients. Molecular Systems Biology, 2021, 17, e10459.	7.2	22
6	Plasma cell-free DNA methylation: a liquid biomarker of hepatic fibrosis. Gut, 2018, 67, 1907-1908.	12.1	21
7	Evaluation of the epigenetic alterations and gene expression levels of HepG2 cells exposed to zearalenone and α-zearalenol. Toxicology Letters, 2020, 326, 52-60.	0.8	21
8	Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation. Journal of Cystic Fibrosis, 2017, 16, 124-131.	0.7	20
9	Clinical and molecular evaluation of MEFV gene variants in the Turkish population: a study by the National Genetics Consortium. Functional and Integrative Genomics, 2022, 22, 291-315.	3.5	7
10	Advances in the epigenetics of fibroblast biology and fibrotic diseases. Current Opinion in Pharmacology, 2019, 49, 102-109.	3.5	5